skip to navigation skip to content
 

Accelerate Plus

Back to Ventures

These ventures have been with Accelerate Cambridge for over six months and are looking at raising their seed round.

Anvil

 Anvil is a tool that takes the pain out of software development, without sacrificing power. Companies are best placed to know their own businesses and develop their own business process tools, but developing web applications is hugely slow and complicated. Anvil's visual designer, simple Python code environment and "batteries-included" philosophy makes business application development faster, easier and more agile.

Visit the Anvil website

Anvil logo

BioPhonics (formerly TunedIn Dx)

BioPhonics is developing consumer and medical devices to automatically detect abnormalities from bodily sounds. They have developed a prototype of an intelligent stethoscope capable of automatic detection of heart diseases. The company's mission is to produce innovative technology to improve early detection of diseases.

Visit the BioPhonics website

BioPhonics logo

Capito Systems

Capito Systems (est. 2012), also trading as capito.ai, specialises in the contextual understanding of natural language (NLU). We have built a high performance NLU cloud platform that delivers application-specific semantic understanding of free-form voice and text inputs at speed and scale. Applications include intelligent voice control, conversational interfaces like chat bots, and semantic search. Our technology is platform-independent and easy to integrate via our APIs. We are able to ‘bootstrap’ NLU models quickly using the latest machine learning techniques coupled with our streamlined development workflows in support of rapid prototyping & testing. Unlike other NLP/NLU solutions, including the “open developer platforms” offered by major players like Amazon, Microsoft and Facebook, ours is a premium NLU product customised for each use case by our in-house experts, as we seek to develop long-term relationships with our clients.

Visit the Capito Systems website

Capito.ai logo

Flit

Flit (formerly Hinton Bikes) is developing a new electric bike that is designed from the ground up to make it convenient for more people to cycle in our increasingly congested and polluted cities. It folds down small enough to take on a train, is light enough to carry upstairs, and is smart enough to tell you when to pump up your tyres. When you get home, simply drop it into its dock for charging. Our mission is to make riding a bike more convenient and reliable than driving a car so that we can get more people cycling in our cities.

Visit the Flit website

Flit logo

omma.tech

omma.tech intends to be the world leader in smart pest detection. Our core technology is an ultra-low-power, insect monitoring sensor that can detect infestations early. By allowing earlier, cheaper intervention we aim to put a significant dent in the global $70 billion annual cost of invasive insect pests.

Omma Tech logo

PHARMeNABLE

PharmEnable explores new areas of chemical space that no one else is currently searching to enable the development of vital new medicines.

Visit the PHARMeNABLE website

Pharmenable logo

POCKiT diagnostics

POCKiT diagnostics is a UK- and Ireland-based startup company aimed at improving diagnosis of brain stroke. Stroke is the third leading cause of death in the Western world and the first cause of physical disability and dementia in adults. Every year 15 million people in the world suffer a stroke; of these, five million die and another five million suffer permanent disability as a consequence of the stroke. Events of brain stroke can occur upon blockage or rupture of blood vessels, giving rise to ischemic stroke (AIS) or intracerebral haemorrhage (ICH), respectively. Patients suffering from AIS or ICH are treated with thrombolytic or pro-coagulant therapy, respectively. Early and reliable diagnosis of the type of stroke is fundamental, as a very narrow time window (four and a half hours) is available for the treatment to be delivered before brain damage becomes permanent. Accurate diagnosis of stroke is paramount, as erroneous administration of thrombolytic or pro-coagulant agents can lead to permanent disability or death. Currently, diagnosis of stroke is performed with computed tomography (CT), which has a high sensitivity for the diagnosis of ICH, but not of AIS. Moreover, CT takes valuable time and is not always readily available in emergency situations, thus delaying treatment of stroke patients and increasing the risk of stroke morbidity and mortality. 

So how is POCKiT going to improve this? After an ischemic or haemorrhagic stroke, specific molecules (biomarkers) are released into our blood. POCKiT is developing a diagnostic device for the rapid diagnosis of AIS and ICH patients. Our innovation is the application of rapid immune-based detection of stroke-specific biomarkers to provide diagnosis of stroke in less than 20 minutes. This diagnostic application can be operated by anyone without the use of laboratory equipment, or individuals trained in chemical analysis. Moreover, our device will be very cheap and highly portable, being able to fit in your pocket. In contrast with other diagnostic tools for stroke that deploy individual or small sets of biomarkers for stroke diagnosis, our device can detect up to 10 different biomarkers, thus significantly improving specificity and sensitivity of diagnosis. We have developed a panel of positive and negative biomarkers for AIS and ICH, potentially allowing to distinguish these conditions univocally. The combination of a rapid diagnostic device, together with our unique panel of stroke subtype-specific biomarkers will allow accurate, fast and cheap diagnosis of stroke patients, potentially leading to faster treatment and reducing disability and death of stroke patients.

Pockit diagnostics logo

SmartBell

Smartbell offers a simple precision agriculture solution for livestock rearing and management. The Smartbell system implements a fully-automated solution for livestock management, including distress alerts, herd analysis and customised farm management reports. Using advanced analytics on data gathered from animal wearables, Smartbell also cross references regional data to better understand resource utilisation and promote proven best practices.

Watch the SmartBell team in discussion with Luther Phillips

Visit the Smartbell website

Smartbell logo

Solidi

Digital currencies represent the future of global on and offline payments. They are fast, cheap, convenient, irreversible and do not rely on a central authority to oversee and run them. They are not limited by geography or nationality and enable payments to be made between people on opposite sides of the globe in seconds lowering the barrier to global business and travel. At the same time, their design and cost structure enable the 2.5 billion unbanked adults worldwide (over 60 per cent of the world's adult population) to finally have a method of transacting and saving out with the cash economy. 

Solidi aims to make buying, selling, spending and holding digital currencies as easy as using cash, while retaining all the benefits of an unforgeable digital token. 

We provide a UK-based, person-to-person matching exchange tightly integrated with the UK Faster Payments System, a mobile app to buy and sell on the exchange, monthly savings options, and an easy to use mobile wallet which supports repurchasing digital currencies as you spend them. 

We are regulated by HMRC as a Bureau de Change and are actively pursuing registration with the FCA as a Money Services Business. Our founders have substantial experience in FinTech and mobile having worked at major investment banks and mobile technology firms.

contact@solidi.co

Visit the Solidi website

Solidi logo

SPIREA

SPIREA is a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

The technology is based on biodegradable polymeric formulations of a combination of drugs for targeted and sustained release that will ultimately improve the efficacy and safety of treatments and patient compliance and comfort. This means a simpler, safer and more effective treatment for various diseases and a pioneering strategy in the management of diseases by combination therapy.

SPIREA aims to establish the polymer platform as a major player in the drug delivery space by partnering with pharmaceutical and biotech companies.

SPIREA logo

Swift Molecular Diagnostics

Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.

We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.

Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips

SwiftDX